Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Completed · Phase 3 · Has a placebo group

Conditions studied: Gastric, or Gastroesophageal Junction Adenocarcinoma

In brief

This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Key facts

Study ID

NCT03777657

Run by

BeiGene

People needed

997

Starts

2018-12-13

Expected to finish

2024-08-27

Last updated by the study team

2025-02-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Southeastern Regional Medical Center — Newnan, Georgia, United States
• Ohio State University Hospital — Columbus, Ohio, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Reading Hospital — West Reading, Pennsylvania, United States
• Tennessee Oncology, Pllc Nashville — Nashville, Tennessee, United States
• The First Affiliated Hospital of Bengbu Medical College — Bengbu, Anhui, China
• Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital — Hefei, Anhui, China
• The Second Hospital of Anhui Medical University — Hefei, Anhui, China
• Peking University Third Hospital — Beijing, Beijing Municipality, China
• Beijing Chao Yang Hospital — Beijing, Beijing Municipality, China
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China
• Beijing Friendship Hospital, Capital Medical University — Beijing, Beijing Municipality, China
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China
• Peking Union Medical College Hospital — Beijing, Beijing Municipality, China
• Chinese Pla General Hospital — Beijing, Beijing Municipality, China
• Beijing Luhe Hospital, Capital Medical University — Beijing, Beijing Municipality, China
• Daping Hospital, Third Military Medical University — Chongqing, Chongqing Municipality, China
• The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China
• Fujian Cancer Hospital — Fuzhou, Fujian, China
• The First Hospital of Lanzhou University — Lanzhou, Gansu, China
• Foshan First Peoples Hospital — Foshan, Guangdong, China
• Sun Yat Sen University Cancer Center — Guangzhou, Guangdong, China
• Guangdong Provincial Peoples Hospital — Guangzhou, Guangdong, China
• Shenzhen Peoples Hospital — Shenzhen, Guangdong, China
• University of California Davis Health System — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.